Estimating survival in patients with non-small-cell lung cancer and brain metastases: A verification of the graded prognostic assessment for lung cancer using molecular markers (lung-molgpa)

Abstract

Purpose: A new tool based on clinical characteristics and molecular factors (Lung-molGPA) was developed to predict the survival of patients with non-small-cell lung cancer but was has not been validated. This study aims to validate the feasibility of the Lung-molGPA in NSCLC. Patients and Methods: Patients diagnosed NSCLC between Feb 2012 and July 2018 were retrospectively reviewed and scored using the Lung-molGPA tool to compare clinical out-comes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by Cox regression analyses. Results: A total of 618 patients (524 adenocarcinoma [ADC], 94 non-adenocarcinoma [non-ADC]) were collected. For all patients, the median survival time (MST) was 33.0 months (33.6 and 28 months in the ADC and non-ADC groups, respectively; p = 0.21). In the ADC group, the MST for patients with a Lung-molGPA score of 3.5 to 4 was more than 4 years, while the MST was only 25 months in patients scoring 0–1, 30.0 months in patients scoring 1.5–2, and 35.0 months for scores of 2.5–3 (p = 0.048). For the non-ADC group, the MST for scores 0–1, 1.5–2, 2.5–3, and 3.5–4 were 12.0, 20.2, 29.0, and 33.0 months, respectively (p = 0.017). Conclusion: Our findings provided evidence validating the Lung-molGPA score as a useful tool to determine treatment strategies and to predict prognosis. The model is still exploratory and needs to be evaluated further in combination with additional prognostic markers.